A Stanford anesthesiologist deconstructs the component parts of what it means to undergo a psychedelic trip.

While psilocybin remains a Schedule I drug under the Federal Controlled Substances Act, at least a dozen other states are monitoring Oregon and drafting their own plans to decriminalize psychedelic substances.

A new study published in JAMA Health Forum has highlighted this surge, noting a 1250% rise in microdosing-related Google searches from 2015 to 2023, with over three million searches in 2023 alone.

Diamond Shruumz products are now linked to illnesses in 20 states. The FDA and Centers for Disease Control (CDC) are working in partnership with the USA’s poison centers, and state and local partners.

There’s no substantive change from its draft evidence report’s determination, or from the vote of its independent panel which resoundingly rejected the intervention.

The study, based on a national survey, found that about 12% of respondents reported using psilocybin at some point in their lives, with 3.1% using it in the past year. This translates to an estimated 8 million American adults who used psilocybin in 2023 alone.

Psychedelic therapy training company Fluence partnered with psychedelic healthcare insurance plans provider Enthea to expand reimbursement for services from Fluence-trained clinicians offering ketamine-assisted therapy.

A bipartisan bill that would have allowed three counties to operate facilities for three years where veterans and former first responders could use psilocybin under the supervision of a licensed physician died in committee on Tuesday.

Studies will focus on mental and physical health applications as well as the societal and economic impact of Colorado’s Magic Mushrooms Law.

Although some researchers argue that a psychedelic experience is essential for a long-term improvement in mental health, nobody knows for sure whether it will be possible to retain therapeutic benefit while avoiding the trip.

Gov. Katie Hobbs (D) said, “Arizonans with depression and PTSD deserve access to treatments that may be seen as outside the mainstream. But they should not be the subject of experiments for unproven therapies with a lack of appropriate guardrails.”

Older individuals who have used psychedelics tend to exhibit better cognitive functioning and fewer depressive symptoms compared to those who have not, according to new research.

If enacted into law, the Department of Human Services (DHS) would be authorized to license psilocybin-assisted therapy centers in the state, where trained facilitators could administer the psychedelic.

Over the past few years, sources at the company have repeatedly told Psychedelic Alpha that it had not filed any patents, to their knowledge, meaning it’s unclear the extent to which portions of its staff were left in the dark regarding its IP strategy.

The move comes weeks after a Senate committee effectively killed a broader bill that would have legalized psychedelic service centers where adults 21 and older could have accessed psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators.

At least eight people have fallen ill after eating Diamond Shruumz products, including several who had seizures or needed to be put on ventilators.

Psychedelics show promise in treating chronic pain in ways that resemble their power to treat depression and other mental illnesses: They shake up the brain’s well-trodden neural pathways.

The poll, from Stockton University’s William J. Hughes Center for Public Policy, found that 55 percent of respondents support legalizing psilocybin for medical use with a under doctor’s supervision. Just 20 percent of respondents were opposed, while 24 percent said they weren’t sure.

Only one committee member said that the benefits of the treatment outweigh the risks as presented, but the other 10 voted that they did not.

Unsurprisingly, a major area of concern for ICER, and NE-CEPAC, was the de facto unblinding of participants and study therapists in the two Phase 3 studies.